RdRp

WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 8, 2025-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that data from the Company’s Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus (RSV) has been accepted for an oral presentation as an ePoster at the European Society of Clinical Microbiology & Infectious Diseases Global 2025 (ESCMID, formerly ECCMID) being held April 11-15, 2025 in Vienna, Austria. The oral ePoster presentation will include results from a Phase 2a human challenge study of EDP-323, a first-in-class, oral, non-nucleoside small-molecule inhibitor of the RSV polymerase (L-protein), which were announced in September 2024 and highlight new data on respiratory mucus production. ePoster Title: “EDP-323, a First-in-Class, Oral, RSV L-Protein Inhibitor Reduces Disease Severity (Respiratory Mucus Production) and Accelerates Viral Clearance in a Human Viral Challenge Study” ePoster Number: E0289 Abstract Number: 04019 Date and Time: April 13, 2025, 8:30 a.m. CEST/ 2:30 a.m. EDT Session Location: Arena 1 Session Title: Novel Approaches to Antiviral Therapy Presenter: John P. DeVincenzo, M.D. The scientific program for ESCMID Global 2025 can be found here. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. View source version on businesswire.com: https://www.businesswire.com/news/home/20250408012708/en/ Media and Investor Contact Jennifer Viera 617-744-3848 jviera@enanta.com Source: Enanta Pharmaceuticals, Inc.

WATERTOWN, Mass.--(BUSINESS WIRE)--Mar. 12, 2025-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that an oral presentation and three posters, including one late breaker, highlighting the company’s respiratory syncytial virus (RSV) program, will be presented at the 13th International RSV Symposium (RSV 2025) being held March 12-15 at Bourbon Cataratas do Iguazu, in Iguazu Falls, Brazil. Results from a Phase 2 human challenge study of EDP-323, an RSV L-protein inhibitor, which were announced in September 2024, will be highlighted in an oral presentation. Data from a Phase 2 study of zelicapavir, an N-protein inhibitor, for the treatment of RSV in young children will be presented in a late breaker poster. An additional poster will highlight distinctions among fusion, N, and L inhibitors with respect to preclinical antiviral effect and resistance profiles, while a third poster will detail PK and PK/PD results from the EDP-323 Phase 2 human challenge study. Oral Presentation: Date: Friday, March 14, 2025 Time: 12:00 – 12:15 PM Brasília Time (BRT)/11:00 – 11:15 AM Eastern Daylight Time (EDT) Session Name: RSV Monoclonal Antibodies and Antivirals Abstract ID: ARBI0162 Title: “EDP-323, a First-in-Class, Once-Daily, Oral Non-nucleoside L-Protein, Replication Inhibitor Antiviral for the Treatment of RSV: Results from a Phase 2a Human Viral Challenge Study” Location: Bourbon Cataratas do Iguazu, Bourbon Ballroom Presenter Name: John P. DeVincenzo, M.D. Late Breaker Poster Presentation: Date: Friday, March 14, 2025 Time: 4:15 – 5:15 PM BRT/3:15 – 4:15 PM EDT Session Name: RSV Monoclonal Antibodies and Antivirals Abstract ID: ARBI0332 Poster Number: 253 Title: “A Phase-2 Double-Blind Placebo Controlled International Trial of Zelicapavir for Treatment of RSV in Young Children” Location: Bourbon Cataratas do Iguazu, Pavilion C Presenter: John P. DeVincenzo, M.D. Poster Presentations: Date: Friday, March 14, 2025 Time: 4:15 – 5:15 PM BRT/3:15 – 4:15 PM EDT Abstract ID: ARBI0249 Poster Number: 161 Title: “In Vitro Characterization of Respiratory Syncytial Virus Inhibitors” Location: Bourbon Cataratas do Iguazu, Pavilion C Presenter: Michael Rhodin, Ph.D. Date: Friday, March 14, 2025 Time: 4:15 – 5:15 PM BRT/3:15 – 4:15 PM EDT Abstract ID: ARBI0158 Poster Number: 153 Title: “EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: PK and PKPD Results from a Phase 2 Challenge Study in Healthy Participants Infected with RSV” Location: Bourbon Cataratas do Iguazu, Pavilion C Presenter: Kimberly Elmore (Mills), PharmD Further information about RSV 2025 can be found here. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information. View source version on businesswire.com: https://www.businesswire.com/news/home/20250312968329/en/ Jennifer Viera 617-744-3848 jviera@enanta.com Source: Enanta Pharmaceuticals, Inc.

2025年1月29日，中国科学院微生物研究所邓涛研究员与高福院士团队合作在Nucleic Acids Research在线发表了题为Influenza A virus NS2 protein acts on vRNA-resident polymerase to drive the transcription to replication switch 的研究论文，该研究揭示了NS2蛋白在病毒感染过程中动态调控病毒RNA由转录向复制转换、从而发挥“开关”功能的作用机制。 在流感病毒生命周期中，病毒基因组RNA在早期进行高效转录（vRNA→mRNA）来合成病毒的蛋白质，而在后期主要进行病毒基因组高效复制（vRNA→cRNA→vRNA）来合成更多的子代病毒基因组，这种由早期转录优势向后期复制优势转换的发生机制长期未解。邓涛团队前期研究首次报道，病毒早期表达蛋白NS1和晚期表达蛋白NS2参与动态调控病毒RNA的转录与复制，其中，NS2蛋白可发挥抑制转录和促进复制的双重功能（Journal of Virology, 2023）；利用重组突变病毒感染系统揭示了NS2蛋白通过与病毒聚合酶（RdRp）协同作用发挥促进复制功能（Journal of Virology, 2024）；通过解析病毒NS2-RdRp复合体的高分辨率结构（~3.0 Å），首次揭示了NS2通过干扰RdRp与宿主Pol II CTD结合从而抑制转录的分子机制（EMBO Reports, 2024）。 在此基础上，该论文首先利用基于病毒RNA启动子序列突变建立的流感病毒RNA单向复制研究系统，发现NS2蛋白能够显著促进病毒RNA复制第一步vRNA→cRNA合成；通过vRNA和cRNA启动子元素移植实验发现RNA启动子特异性核苷酸是决定RNA合成活性的关键特征；利用高灵敏的体内互作分析NanoBiT技术，进一步发现NS2特异性作用于vRNA结合的病毒RNA聚合酶来发挥促进病毒RNA复制的调控作用。最后，体外病毒RNA复制系统实验也进一步证实NS2蛋白主要促进病毒RNA复制第一步vRNA→cRNA合成。以上研究成果创新性地提出了流感病毒复制调控新机理，为开发针对流感病毒RNA合成过程的新型抗病毒策略提供了重要思路。 论文链接： https://doi.org/10.1093/nar/gkaf027 原文链接： https://im.cas.cn/xwzx2018/kyjz/202502/t20250206_7525056.html 本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！